BioWorld

Sep. 23, 2005

Private Deal Brings $31M To Memory For Research

Months after losing part of a partnership, Memory Pharmaceuticals Corp. extended its runway through the end of next year by raising about $31 million in gross proceeds through a private stock and warrant placement. (BioWorld Today) Read More

Investors: Regulatory Rules Make Exit Paths Expensive

Snail's Cancer Role Expands From Metastasis To Relapse

CytRx Starting Phase II With Arimoclomol In ALS Patients

FDA Request Delays Decision On Avanir's Neurodex In PBA

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...

Illustration of leg anatomy with target around knee

Lilly’s retatrutide shows solid weight loss, reduced knee pain

BioWorld

Eli Lilly and Co.’s latest phase III results for the obesity and overweight populations suggest its triple agonist, retatrutide, can deliver significant weight...